Leerink Partnrs Issues Optimistic Outlook for NAMS Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Leerink Partnrs boosted their Q3 2025 earnings per share estimates for NewAmsterdam Pharma in a report issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now forecasts that the company will post earnings of ($0.41) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.43) EPS.

A number of other analysts also recently commented on NAMS. Citigroup assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They set a “buy” rating and a $42.00 target price on the stock. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, July 5th. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They set an “overweight” rating and a $42.00 target price on the stock. Stifel Nicolaus assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, June 10th. They set a “buy” rating and a $44.00 target price on the stock. Finally, The Goldman Sachs Group assumed coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a “neutral” rating and a $27.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.20.

NewAmsterdam Pharma Stock Performance

NAMS opened at $25.31 on Monday. The business’s fifty day moving average is $20.73 and its two-hundred day moving average is $19.98. The company has a market cap of $2.84 billion, a price-to-earnings ratio of -15.62 and a beta of -0.02. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.37. The firm had revenue of $19.15 million for the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in NAMS. Letko Brosseau & Associates Inc. acquired a new position in NewAmsterdam Pharma in the second quarter valued at $213,000. Geode Capital Management LLC increased its stake in NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock valued at $1,800,000 after purchasing an additional 13,629 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in NewAmsterdam Pharma in the second quarter valued at $6,392,000. Teacher Retirement System of Texas acquired a new position in NewAmsterdam Pharma in the second quarter valued at $212,000. Finally, Aberdeen Group plc increased its stake in NewAmsterdam Pharma by 95.0% in the second quarter. Aberdeen Group plc now owns 735,032 shares of the company’s stock valued at $13,311,000 after purchasing an additional 358,169 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director James N. Topper purchased 8,584 shares of the business’s stock in a transaction dated Monday, June 16th. The stock was bought at an average cost of $19.50 per share, with a total value of $167,388.00. Following the completion of the acquisition, the director directly owned 3,022,153 shares in the company, valued at $58,931,983.50. The trade was a 0.28% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Douglas F. Kling sold 100,000 shares of the business’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $19.29, for a total value of $1,929,000.00. Following the completion of the transaction, the chief operating officer directly owned 44,000 shares of the company’s stock, valued at approximately $848,760. This trade represents a 69.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders bought 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. Insiders own 20.84% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.